hydration effects glp-1 receptor agonist therapy 2025 UC Davis Health examines systemic impact of GLP-1–based therapies SGLT2 vs GLP-1: Individualizing Diabetes,

Human virome and disease: high-throughput sequencing for virus discovery, identification of phage-bacteria dysbiosis and development of therapeutic approaches with emphasis on the human gut

Just two weeks later, on 1 April 2026, the FDA approved Foundayo, Eli Lillys brand name for orforglipron, making it the first small-molecule, non-peptide oral GLP-1 receptor agonist approved for chronic weight management

Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD

You typically need to meet one of two thresholds: either a BMI of 30 or higher (which meets the clinical definition of obesity), or a BMI of 27 or higher combined with at least one weight-related health condition

Nor are they a cure

Journal reference: Wang, M